The Journal of the American Medical Association called into question published clinical data and authorship surrounding Merck’s Vioxx (rofecoxib) in a scathing editorial. 
The hubbub stems from two articles printed in the April 16 issue, which offer a microscopic look at documents obtained during Vioxx lawsuits and litigation.
JAMA asserts that “clinical trial articles and review articles related to rofecoxib frequently were written by unacknowledged authors who were employees of for-profit information industries…” Merck refuted the charges in a statement claiming that the JAMA reports related to Vioxx “are false, misleading or lack context.”

From the June 01, 2008 Issue of MM+M - Medical Marketing and Media